How Patient Recruitment Numbers Affect End-Stage Renal Disease Dialysis Research
Chronic kidney disease affects more than 800 million people worldwide. In fact, 786,000 Americans are living with end-stage renal disease (ESRD). 71% of whom are undergoing dialysis, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
End-stage renal disease dialysis research plays a crucial role in helping improve quality of life and hopefully find a cure.
What is end-stage renal disease?
Also called kidney failure, end-stage renal disease is a medical condition where the kidney fails to function properly to meet the body’s requirements.
In its early stages, patients with ESRD may not feel any new signs and symptoms. But once it progresses, patients start to experience nausea/vomiting, fatigue/weakness, loss of appetite, swelling on the feet/ankles, changes in urine output, and shortness of breath if fluid accumulation reaches the lungs.
Since ESRD is the late stage of kidney disease, most patients require dialysis to help relieve the body of toxins. Kidney transplants are also common at this stage which is a costly and difficult procedure.
Due to this, many patients who suffer from ESRD are given poor prognoses. However, medical experts believe that there are ways to prevent ESRD and improve the prognosis of patients suffering from it.
With end-stage renal disease dialysis research, patients have the chance to participate in clinical trials to try and find better treatment options.
How do recruitment numbers affect ESRD research?
Although a lot of advancements have happened in the medical world over the last few years, there are still a lot of limitations on how patients with ESRD are treated. End-stage renal disease dialysis research offers hope for patients who have already run out of options.
But researchers still struggle a lot, especially when it comes to reaching enough recruitment numbers to conduct these clinical trials successfully. A lack of participants combined with a lack of resources has resulted to slow progress in many end-stage renal disease dialysis research, and this also means that new treatment options won’t be available right away.
Researchers have dealt with these challenges for many years and it has delayed the opportunity for patients to experience new treatments that will help them manage their disease and prevent any progression that could lead to mortality.
So, if you’re one of the many Americans who are suffering from end-stage renal disease, it’s very important to discuss with your doctor the possibility of participating in clinical trials related to end-stage renal disease dialysis research.
By doing so, you’re not only giving yourself the opportunity to be part of something that could be the cure or solution to end-stage renal disease, but you’re also giving other patients the chance to live better lives in the future.
The National Institute of Clinical Research is an SMO/CRO with offices and labs in the following cities and states: New Jersey, North Carolina, Austin, San Diego, San Francisco, Bakersfield 93309, Fountain Valley 92708, Garden Grove 92840, Hacienda Heights 91745, Huntington Beach 92648, Las Vegas 89106, Long Beach 90806, Los Angeles 90048, Ontario 91762, Rosemead 91770, San Antonio 78207, Santa Ana 92704, Upland 91786, and Westminster 92683.